DD146892A5 - Verfahren zur herstellung eines antihaemophiliefaktorpraeparates aus menschlichem blutplasma - Google Patents
Verfahren zur herstellung eines antihaemophiliefaktorpraeparates aus menschlichem blutplasma Download PDFInfo
- Publication number
- DD146892A5 DD146892A5 DD79216550A DD21655079A DD146892A5 DD 146892 A5 DD146892 A5 DD 146892A5 DD 79216550 A DD79216550 A DD 79216550A DD 21655079 A DD21655079 A DD 21655079A DD 146892 A5 DD146892 A5 DD 146892A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- plasma
- irradiation
- thawed
- blood plasma
- preparation
- Prior art date
Links
- 210000002381 plasma Anatomy 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title abstract description 34
- 238000004519 manufacturing process Methods 0.000 title description 3
- 230000000603 anti-haemophilic effect Effects 0.000 title 1
- 238000010257 thawing Methods 0.000 claims abstract description 19
- 239000000047 product Substances 0.000 claims abstract description 10
- 239000002244 precipitate Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 12
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 abstract description 11
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 3
- 101100275845 Streptococcus pneumoniae (strain ATCC BAA-255 / R6) cshA gene Proteins 0.000 abstract 1
- 101100439746 Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) cinA gene Proteins 0.000 abstract 1
- 101100502016 Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) exp8 gene Proteins 0.000 abstract 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 12
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 12
- 108010054218 Factor VIII Proteins 0.000 description 5
- 102000001690 Factor VIII Human genes 0.000 description 5
- 208000009292 Hemophilia A Diseases 0.000 description 5
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 208000031220 Hemophilia Diseases 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 229960000301 factor viii Drugs 0.000 description 3
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229940105778 coagulation factor viii Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101100522358 Kluyveromyces lactis (strain ATCC 8585 / CBS 2359 / DSM 70799 / NBRC 1267 / NRRL Y-1140 / WM37) PUL3 gene Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000002085 hemarthrosis Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
- H01R13/00—Details of coupling devices of the kinds covered by groups H01R12/70 or H01R24/00 - H01R33/00
- H01R13/46—Bases; Cases
- H01R13/52—Dustproof, splashproof, drip-proof, waterproof, or flameproof cases
- H01R13/5219—Sealing means between coupling parts, e.g. interfacial seal
- H01R13/5221—Sealing means between coupling parts, e.g. interfacial seal having cable sealing means
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK487578 | 1978-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD146892A5 true DD146892A5 (de) | 1981-03-11 |
Family
ID=8137444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD79216550A DD146892A5 (de) | 1978-11-01 | 1979-10-30 | Verfahren zur herstellung eines antihaemophiliefaktorpraeparates aus menschlichem blutplasma |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4251437A (sv) |
| JP (1) | JPS5585523A (sv) |
| AR (1) | AR217576A1 (sv) |
| AT (1) | AT369652B (sv) |
| AU (1) | AU522556B2 (sv) |
| BE (1) | BE879733A (sv) |
| CA (1) | CA1119094A (sv) |
| DD (1) | DD146892A5 (sv) |
| DE (1) | DE2943512A1 (sv) |
| ES (1) | ES485550A1 (sv) |
| FI (1) | FI63521C (sv) |
| FR (1) | FR2440193A1 (sv) |
| GB (1) | GB2034327B (sv) |
| HU (1) | HU180898B (sv) |
| IL (1) | IL58541A (sv) |
| IT (1) | IT1162791B (sv) |
| NL (1) | NL7907984A (sv) |
| NO (1) | NO793501L (sv) |
| OA (1) | OA06368A (sv) |
| SE (1) | SE7909026L (sv) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3033932C2 (de) * | 1980-09-10 | 1984-05-24 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten |
| US4620908A (en) * | 1983-10-03 | 1986-11-04 | Biocell Laboratories, Inc. | Method for destroying microbial contamination in protein materials |
| US4975246A (en) * | 1985-09-30 | 1990-12-04 | Charm Stanley E | High temperature, short time heating system and method of heating heat-sensitive material |
| US4839142A (en) * | 1985-09-30 | 1989-06-13 | Charm Stanley E | High temperature, short time heating system and method of sterilizing or pasteurizing heat sensitive biological fluids |
| FR2634381B1 (fr) * | 1988-07-25 | 1990-09-07 | Morez Jean Bernard | Procede pour la fabrication de medicaments homeopathiques en une seule operation quelque soit la dilution choisie |
| WO1991010450A1 (fr) * | 1990-01-11 | 1991-07-25 | Morez Jean Bernard | Procede pour la fabrication homeopatiques en une seule operation quelque soit la dilution choisie |
| US6187572B1 (en) | 1990-04-16 | 2001-02-13 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants |
| US5418130A (en) * | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
| US5644032A (en) * | 1990-08-06 | 1997-07-01 | Fibrin Corporation | Process for producing fibrinogen concentrates |
| DE4308360C1 (de) * | 1993-03-16 | 1994-10-27 | Transmed Medtech Gmbh | Aufwärm- und Auftaugerät |
| US5362442A (en) * | 1993-07-22 | 1994-11-08 | 2920913 Canada Inc. | Method for sterilizing products with gamma radiation |
| US20040067157A1 (en) * | 1993-07-22 | 2004-04-08 | Clearant, Inc. | Methods for sterilizing biological materials |
| US5616268A (en) * | 1994-07-07 | 1997-04-01 | Microwave Medical Systems | Microwave blood thawing with feedback control |
| US20020077276A1 (en) * | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
| US20040086420A1 (en) * | 2000-03-23 | 2004-05-06 | Macphee Martin J. | Methods for sterilizing serum or plasma |
| US6682695B2 (en) * | 2001-03-23 | 2004-01-27 | Clearant, Inc. | Methods for sterilizing biological materials by multiple rates |
| US6696060B2 (en) | 2001-06-14 | 2004-02-24 | Clearant, Inc. | Methods for sterilizing preparations of monoclonal immunoglobulins |
| US20030031584A1 (en) * | 2001-08-10 | 2003-02-13 | Wilson Burgess | Methods for sterilizing biological materials using dipeptide stabilizers |
| US6946098B2 (en) | 2001-08-10 | 2005-09-20 | Clearant, Inc. | Methods for sterilizing biological materials |
| US7252799B2 (en) | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
| US6749851B2 (en) | 2001-08-31 | 2004-06-15 | Clearant, Inc. | Methods for sterilizing preparations of digestive enzymes |
| US20030095890A1 (en) * | 2001-09-24 | 2003-05-22 | Shirley Miekka | Methods for sterilizing biological materials containing non-aqueous solvents |
| US20110091353A1 (en) * | 2001-09-24 | 2011-04-21 | Wilson Burgess | Methods for Sterilizing Tissue |
| US6783968B2 (en) | 2001-09-24 | 2004-08-31 | Clearant, Inc. | Methods for sterilizing preparations of glycosidases |
| US20030185702A1 (en) * | 2002-02-01 | 2003-10-02 | Wilson Burgess | Methods for sterilizing tissue |
| US20030124023A1 (en) * | 2001-12-21 | 2003-07-03 | Wilson Burgess | Method of sterilizing heart valves |
| US20030180181A1 (en) * | 2002-02-01 | 2003-09-25 | Teri Greib | Methods for sterilizing tissue |
| US20040013562A1 (en) * | 2002-07-18 | 2004-01-22 | Wilson Burgess | Methods for sterilizing milk. |
| US6908591B2 (en) * | 2002-07-18 | 2005-06-21 | Clearant, Inc. | Methods for sterilizing biological materials by irradiation over a temperature gradient |
| US20060226086A1 (en) * | 2005-04-08 | 2006-10-12 | Robinson Thomas C | Centrifuge for blood processing systems |
| DE202010004830U1 (de) | 2010-04-10 | 2010-07-29 | Pelster, Michael, Dipl.-Ing. | Vorrichtung zum Auftauen und/oder Erwärmen von sich in einem Behältnis befindlichen medizinischen Gut |
| US9173248B2 (en) * | 2011-03-14 | 2015-10-27 | Products Support, Inc. | Thawing oven |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2867567A (en) * | 1955-01-21 | 1959-01-06 | Nat Res Dev | Process of preparing anti-haemophilic globulin |
| US3492212A (en) * | 1966-12-01 | 1970-01-27 | Hoffmann La Roche | Ultrasonic treatment of protein materials |
| US3652530A (en) * | 1967-08-28 | 1972-03-28 | American Nat Red Cross | Antihemophilic factor prepared from blood plasma using polyethylene glycol |
| US3645849A (en) * | 1969-04-17 | 1972-02-29 | Gray Ind Inc | Stability of enzymes |
| FR2363577A1 (fr) * | 1976-09-03 | 1978-03-31 | Recherches Hematologiques | Procede simplifie pour preparer avec un rendement eleve du concentre de facteur antihemophilique pur |
-
1979
- 1979-10-23 IL IL58541A patent/IL58541A/xx unknown
- 1979-10-26 AU AU52231/79A patent/AU522556B2/en not_active Ceased
- 1979-10-26 US US06/088,671 patent/US4251437A/en not_active Expired - Lifetime
- 1979-10-27 DE DE19792943512 patent/DE2943512A1/de not_active Withdrawn
- 1979-10-30 BE BE0/197898A patent/BE879733A/fr unknown
- 1979-10-30 ES ES485550A patent/ES485550A1/es not_active Expired
- 1979-10-30 DD DD79216550A patent/DD146892A5/de unknown
- 1979-10-30 IT IT26925/79A patent/IT1162791B/it active
- 1979-10-30 GB GB7937595A patent/GB2034327B/en not_active Expired
- 1979-10-30 FI FI793389A patent/FI63521C/fi not_active IP Right Cessation
- 1979-10-31 AT AT0703979A patent/AT369652B/de not_active IP Right Cessation
- 1979-10-31 NO NO793501A patent/NO793501L/no unknown
- 1979-10-31 SE SE7909026A patent/SE7909026L/sv not_active Application Discontinuation
- 1979-10-31 CA CA000338815A patent/CA1119094A/en not_active Expired
- 1979-10-31 FR FR7927040A patent/FR2440193A1/fr active Granted
- 1979-10-31 NL NL7907984A patent/NL7907984A/nl not_active Application Discontinuation
- 1979-11-01 AR AR278737A patent/AR217576A1/es active
- 1979-11-01 JP JP14051279A patent/JPS5585523A/ja active Pending
- 1979-11-01 HU HU79NO237A patent/HU180898B/hu unknown
- 1979-11-01 OA OA56928A patent/OA06368A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO793501L (no) | 1980-05-05 |
| JPS5585523A (en) | 1980-06-27 |
| BE879733A (fr) | 1980-04-30 |
| OA06368A (fr) | 1981-07-31 |
| AT369652B (de) | 1983-01-25 |
| ES485550A1 (es) | 1980-07-01 |
| HU180898B (en) | 1983-05-30 |
| SE7909026L (sv) | 1980-05-02 |
| IL58541A0 (en) | 1980-01-31 |
| ATA703979A (de) | 1982-06-15 |
| DE2943512A1 (de) | 1980-05-14 |
| CA1119094A (en) | 1982-03-02 |
| GB2034327A (en) | 1980-06-04 |
| US4251437A (en) | 1981-02-17 |
| AU5223179A (en) | 1980-05-08 |
| NL7907984A (nl) | 1980-05-06 |
| FI793389A (fi) | 1980-05-02 |
| IL58541A (en) | 1982-02-28 |
| GB2034327B (en) | 1982-11-17 |
| FI63521B (fi) | 1983-03-31 |
| IT1162791B (it) | 1987-04-01 |
| IT7926925A0 (it) | 1979-10-30 |
| AU522556B2 (en) | 1982-06-10 |
| FR2440193A1 (fr) | 1980-05-30 |
| FI63521C (fi) | 1983-07-11 |
| AR217576A1 (es) | 1980-03-31 |
| FR2440193B1 (sv) | 1983-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD146892A5 (de) | Verfahren zur herstellung eines antihaemophiliefaktorpraeparates aus menschlichem blutplasma | |
| DE3033932C2 (de) | Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten | |
| DE3382716T2 (de) | Verfahren zur Wärmebehandlung von Plasma oder Plasmafraktionen und so erhaltene Zusammensetzungen. | |
| DE2459291C3 (de) | Verfahren zur Herstellung eines antihämophiles Globulin A enthaltenden Konzentrats neben einem Prothrombin- Komplex und einer Lösung von lagerstabilen Serumproteinen | |
| EP0233279B1 (de) | Neuartige verwendung von taurolin | |
| DE3734923C1 (de) | Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt | |
| DE2324717C3 (de) | Verfahren zur Herstellung eines stabilen AHF-Konzentrates (Faktor VIII) | |
| CH645537A5 (en) | Antithrombin product and process for its production | |
| DE1219180B (de) | Verfahren zur Herstellung von prothetischen Vorrichtungen und chirurgischem Naehmaterial | |
| DE1617317A1 (de) | Verfahren zur Herstellung von aktiven,die Wundheilung foerdernden Wirkstoffen aus Knorpelmasse | |
| DE2715832B2 (de) | Verfahren zur Gewinnung von gereinigtem antihämophilem Globulin A (Faktor VIII) | |
| EP0263417A1 (de) | Verwendung von Hyaluronidase | |
| DE3686390T2 (de) | Verfahren zur herstellung vom antihaemophilfaktor (ahf) durch kaeltefaellung und zur verbesserung der loeslichkeit des hergestellten ahf-produktes. | |
| DE1767285B2 (de) | Verfahren zur Herstellung eines stabilen, hochwirksamen AHF-Konzentrates und Mittel zur Behandlung der Hämophilie | |
| DE3019895C2 (sv) | ||
| DE2405002B2 (de) | Lösliches natives Kollagen aus menschlicher Plancenta sowie dieses als therapeutischen Wirkstoff enthaltendes Mittel | |
| DE2703620A1 (de) | Verfahren zur herstellung eines konzentrats des antihaemophiliefaktors | |
| EP0144714A2 (de) | Verfahren zur Herstellung einer Serumproteinlösung | |
| DE1924715C3 (de) | In den Intervertebralraum injizierbares Arzneimittel zur Behandlung des Bandscheibenvorfalles | |
| DE69117920T2 (de) | Zusammensetzung zur stabilisierung von blutplasma im laufe der pasteurisation | |
| EP0967986B1 (de) | VERWENDUNG VON HUMANEM alpha 1-SAUREN GLYCOPROTEIN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN PRÄPARATION | |
| DE2262520B2 (de) | Verfahren zur Herstellung eines lyophilisierten, lagerfähigen Konzentrats aus menschlichem Plasma | |
| EP2826483A2 (de) | Stoffgemisch enthaltend Ribose und Aminosäuren zur Behandlung von Sepsis, Koagulopathien, Knochenheilungsstörungen und/oder Knochenblutungen | |
| AT285048B (de) | Verfahren zur Herstellung einer stabilen Lösung der Plasmaeiweißkörper Albumin sowie α- und β-Globuline | |
| DE2232949A1 (de) | Verfahren zum herstellen von nicht oxydiertem, reinem zuckerrohrsaft |